In partnership with the Q-CROC, Esperas invests up to $7M in a clinical trial!

For the well-being of cancer patients, Q-CROC and Esperas Pharma announced that they will be testing a new treatment over the next 3.5 years. They have teamed up to develop an all-new oral drug for patients with advanced or metastatic cancer, including triple negative breast, colorectal and ovarian cancers. Esperas is expected to invest up to $7M in this clinical trial.

Q-CROC receives a $2M grant!

At the 6th Annual National Conference to Defeat Cancer, organized by Coalition Priorité Cancer, Merck Canada reinforced the company’s continued commitment to the Quebec life sciences research innovation sector by announcing a $2M grant to Q-CROC.

​

The grant received by Q-CROC will go towards biomarker-driven clinical research for personalized medicine in cancer, notably in the framework of a public-private partnership put forward by Q-CROC and the newly-formed Centre of Excellence Exactis Innovation (prev. PreThera Research).

Q-CROC secures $18,4M grant to improve clinical research in cancer.

Q-CROC was awarded a $9.2M investment from the Quebec government over four years as part of the Fonds de partenariat pour un Québec innovant et en santé (FPQIS). This public-private partnership was formally announced on February 14th, 2014 by Mr. Nicolas Marceau, the Quebec Minister of Finance and Economy. Private partners from the pharmaceutical industry and SMEs are providing matching funds, for a total investment of $18.4M.

$15M investment to create Exactis (prev. PreThera)

The Centre of Excellence Exactis Innovation (previously known as PreThera Research), a non-for-profit organisation with its head office located in Montreal, is, among many things, issued from the vision of the Quebec Clinical Research Organisation in Cancer (Q-CROC) who will be one of the major medical and university partners in this initiative. PreThera Research will be built on solid grounds that comprise of a multidisciplinary and multi-institutional pan-Quebec network of worldwide renowned expertise in cancer research, and of local, national and international collaborations with public and private partners.

Q-CROC takes part in major partnership for personalized medicine

Q-CROC welcomes the announcement made today by Mr. Nicolas Marceau and Ms. Elaine Zakaïb, about a $10M investment in the Personalized Medicine Partnership for Cancer (PMPC). PMPC will be supported in its deployment by Q-CROC.

Imprecedented partnership in the health sector

Under the ausprices of the FRSQ, Pfizer Canada injects $10M into a Quebec fund for public-sector research in human health.